Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, Ito A, Ishikawa J, Eto T, Morishima S, Kawakita T, Itonaga H, Uchida N, Tanaka M, Akizuki K, Ishitsuka K, Ohigashi H, Ota S, Ando T, Kanda Y, Fukuda T, Atsuta Y, Fuji S; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Yoshimitsu M, et al. Among authors: muranushi h. Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835. Online ahead of print. Br J Haematol. 2024. PMID: 39425565
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
Naka R, Kondo T, Nishikubo M, Muranushi H, Ueda Y, Oka T, Wada F, Kanda J, Yamamoto S, Watanabe M, Okada S, Imada K, Nakabo Y, Mizutani Y, Nannya Y, Ogawa S, Ishikawa T. Naka R, et al. Among authors: muranushi h. Am J Hematol. 2023 Sep;98(9):E251-E254. doi: 10.1002/ajh.27012. Epub 2023 Jun 28. Am J Hematol. 2023. PMID: 37381699 Free article. No abstract available.
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H, Kanda J, Kobayashi M, Maeda T, Kitano T, Tsuji M, Ueda Y, Ishikawa T, Nohgawa M, Watanabe M, Imada K, Moriguchi T, Itoh M, Ohno H, Yonezawa A, Hirata H, Arima N, Asagoe K, Anzai N, Nagata K, Yasuno S, Kuwabara Y, Kitao H, Kim I, Kawagishi K, Ueshima K, Tominari S, Nakayama T, Yamashita K, Takaori-Kondo A. Muranushi H, et al. Hematology. 2022 Dec;27(1):239-248. doi: 10.1080/16078454.2022.2032915. Hematology. 2022. PMID: 35152852 Free article. Clinical Trial.
Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality.
Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, Katayama Y, Shiratori S, Ota S, Matsuoka KI, Onizuka M, Fukuda T, Atsuta Y, Murata M, Terakura S, Nakasone H. Akahoshi Y, et al. Among authors: muranushi h. Clin Infect Dis. 2021 Aug 2;73(3):e620-e628. doi: 10.1093/cid/ciaa1871. Clin Infect Dis. 2021. PMID: 33341890
Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.
Morishima S, Fukuda T, Doki N, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Morishima S, et al. Bone Marrow Transplant. 2021 Mar;56(3):646-654. doi: 10.1038/s41409-020-01070-3. Epub 2020 Oct 9. Bone Marrow Transplant. 2021. PMID: 33037403
Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, Eto T, Hidaka M, Choi I, Miyamoto T, Uchida N, Moriuchi Y, Miyazaki Y, Fukuda T, Ichinohe T, Atsuta Y; ATL Working Group of the Japanese Society for Hematopoietic Cell Transplantation; Kato K. Muranushi H, et al. Bone Marrow Transplant. 2021 Jan;56(1):298. doi: 10.1038/s41409-020-01037-4. Bone Marrow Transplant. 2021. PMID: 32843726 Free PMC article. No abstract available.
GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, Eto T, Hidaka M, Choi I, Miyamoto T, Uchida N, Moriuchi Y, Miyazaki Y, Fukuda T, Ichinohe T, Atsuta Y; ATL Working Group of the Japanese Society for Hematopoietic Cell Transplantation; Kato K. Muranushi H, et al. Bone Marrow Transplant. 2021 Jan;56(1):155-166. doi: 10.1038/s41409-020-00996-y. Epub 2020 Jul 14. Bone Marrow Transplant. 2021. PMID: 32665675 Free PMC article.
12 results